Clinical observation of efficacy of combinative usage of ipratropium bromide and small dosage of theophylline on patients with COPD / 中国临床药理学与治疗学

ABSTRACT

AIM: To contrastively observe the effects of combinative usage of ipratropium bromide, anti cholinergic inhalant and the small dosage of controlled release theophylline tablets or salbutamol on the patients with COPD. Clinical observation of efficacy of combinative usage of ipratropium bromide and small dosage of theophylline on patients with COPD$$$$ WENG Hai xia, DAI Yuan rong, WU Cheng yun, LIN Jie Department of Respiratory, the Second Affiliated Hospital of Wenzhou Medical College, Wenzhou 325027, Zhejiang, China ABSTRACT AIM: To contrastively observe the effects of combinative usage of ipratropium bromide, anti cholinergic inhalant and the small dosage of controlled release theophylline tablets or salbutamol on the patients with COPD. [WTHZ METHODS: Forty patients with stable COPD were randomly divided into two groups ( n =20 in each) theophylline group or salbutamol group. In theophylline group, each case inhaled 2 puffs of ipratropium bromide ter in die, meanwhile take 0.1 g ophylline capsule orally every 12 hours, measured the maximum and minimum concentration of ophylline. In salbutamol group, each case inhaled 2 puffs of ipratropium bromide and salbutamol ter in die. During 8 weeks trial, the base FEV 1.0 before using medicine and the FEV 1.0 when all the drug were stopped at the end of 1st, 4th, and 8th week was measured, separately. The FEV 1.0 amelioration ratio (△′FEV 1.0 ) compared with base FEV 1.0 was obtained , and another FEV 1.0 amelioration ratio (△FEV 1.0 ) was also detected after bronchodilatation test by salbutamol. Furthermore, PEFR aberration rate was evaluated by measuring peak expiratory flow rate in morning and evening daily. The maximum concentration of ophylline is 8.7 ? 2.1 mg?L -1 , the minimum is 6.1 ? 2.3 mg?L -1 . RESULTS: △FEV 1.0 increased markedly at end of 8th week in theophylline group (P